Cargando…

Dysglycemia Shapes Visceral Adipose Tissue’s Response to GIP, GLP-1 and Glucagon in Individuals with Obesity

Visceral adipose tissue (VAT) metabolic fingerprints differ according to body mass index (BMI) and glycemic status. Glucagon-like peptide 1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP) and glucagon are gut-associated hormones that play an important role in regulating energy and glucos...

Descripción completa

Detalles Bibliográficos
Autores principales:	Morais, Tiago, Seabra, Alexandre L., Patrício, Bárbara G., Carrageta, David F., Guimarães, Marta, Nora, Mário, Oliveira, Pedro F., Alves, Marco G., Monteiro, Mariana P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10224016/ https://www.ncbi.nlm.nih.gov/pubmed/37233628 http://dx.doi.org/10.3390/metabo13050587

Ejemplares similares

Visceral Adipose Tissue Displays Unique Metabolomic Fingerprints in Obesity, Pre-Diabetes and Type 2 Diabetes
por: Morais, Tiago, et al.
Publicado: (2021)

Adipose Tissue Epigenetic Profile in Obesity-Related Dysglycemia - A Systematic Review
por: Andrade, Sara, et al.
Publicado: (2021)

The Effects of Dual GLP-1/GIP Receptor Agonism on Glucagon Secretion—A Review
por: Mathiesen, David S., et al.
Publicado: (2019)

Monomeric GLP-1/GIP/glucagon triagonism corrects obesity, hepatosteatosis, and dyslipidemia in female mice
por: Jall, Sigrid, et al.
Publicado: (2017)

Structural insights into multiplexed pharmacological actions of tirzepatide and peptide 20 at the GIP, GLP-1 or glucagon receptors
por: Zhao, Fenghui, et al.
Publicado: (2022)

Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice
por: Knerr, Patrick J., et al.
Publicado: (2022)

Nephroprotective Properties of the Glucose-Dependent Insulinotropic Polypeptide (GIP) and Glucagon-like Peptide-1 (GLP-1) Receptor Agonists
por: Bulum, Tomislav
Publicado: (2022)

A Dual GLP-1/GIP Receptor Agonist Does Not Antagonize Glucagon at Its Receptor but May Act as a Biased Agonist at the GLP-1 Receptor
por: Al-Zamel, Noura, et al.
Publicado: (2019)

The Role of GIP in the Regulation of GLP-1 Satiety and Nausea
por: Hayes, Matthew R., et al.
Publicado: (2021)

Effect of Age on Blood Glucose and Plasma Insulin, Glucagon, Ghrelin, CCK, GIP, and GLP-1 Responses to Whey Protein Ingestion
por: Giezenaar, Caroline, et al.
Publicado: (2017)

Fructose stimulates GLP-1 but not GIP secretion in mice, rats, and humans
por: Kuhre, Rune E., et al.
Publicado: (2014)

GIP and GLP‐1, the two incretin hormones: Similarities and differences
por: Seino, Yutaka, et al.
Publicado: (2010)

GLP1 and GIP are involved in the action of synbiotics in broiler chickens
por: Kolodziejski, Pawel Antoni, et al.
Publicado: (2018)

Glucagon-like peptide 1 and dysglycemia: Conflict in incretin science
por: Singh, Awadhesh Kumar
Publicado: (2015)

Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist
por: Willard, Francis S., et al.
Publicado: (2020)

Special Report: Potential Strategies for Addressing GLP-1 and Dual GLP-1/GIP Receptor Agonist Shortages
por: Whitley, Heather P., et al.
Publicado: (2023)

The Incretin Effect in Female Mice With Double Deletion of GLP-1 and GIP Receptors
por: Ahrén, Bo, et al.
Publicado: (2019)

Glucagon, GLP-1 and Thermogenesis
por: González-García, Ismael, et al.
Publicado: (2019)

The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect
por: Fisman, Enrique Z., et al.
Publicado: (2021)

GLP1 and glucagon co-secreting pancreatic neuroendocrine tumor presenting as hypoglycemia after gastric bypass
por: Guimarães, Marta, et al.
Publicado: (2015)

GLP-1 Increases Circulating Leptin Levels in Truncal Vagotomized Rats
por: Morais, Tiago, et al.
Publicado: (2023)

GIP Does Not Potentiate the Antidiabetic Effects of GLP-1 in Hyperglycemic Patients With Type 2 Diabetes
por: Mentis, Nikolaos, et al.
Publicado: (2011)

Postprandial levels of GLP-1, GIP and glucagon after 2 years of weight loss with a Paleolithic diet: a randomised controlled trial in healthy obese women
por: Otten, Julia, et al.
Publicado: (2019)

Serum Glucose-Dependent Insulinotropic Polypeptide (GIP) and Glucagon-Like Peptide-1 (GLP-1) in association with the Risk of Gestational Diabetes: A Prospective Case-Control Study
por: Mosavat, Maryam, et al.
Publicado: (2020)

“Let's Stay Together”; GIP and GLP-1 dual agonism in the treatment of metabolic disease
por: DiMarchi, Richard D.
Publicado: (2018)

Insights Into GLP-1 and GIP Actions Emerging From Vildagliptin Mechanism Studies in Man
por: Foley, James E.
Publicado: (2019)

Single-Cell Mapping of GLP-1 and GIP Receptor Expression in the Dorsal Vagal Complex
por: Ludwig, Mette Q., et al.
Publicado: (2021)

Effects of Renal Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide
por: Urva, Shweta, et al.
Publicado: (2021)

What combines best with GLP-1 for obesity treatment: GIP receptor agonists or antagonists?
por: Holst, Jens Juul
Publicado: (2021)

Effects of Hepatic Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide
por: Urva, Shweta, et al.
Publicado: (2022)

Contribution of GIP and GLP-1 to the Insulin Response to Oral Administration of Glucose in Female Mice
por: Ahrén, Bo
Publicado: (2023)

Glucagon-like peptide 1 (GLP-1)
por: Müller, T.D., et al.
Publicado: (2019)

Link Between GIP and Osteopontin in Adipose Tissue and Insulin Resistance
por: Ahlqvist, Emma, et al.
Publicado: (2013)

Designing a Dual GLP-1R/GIPR Agonist from Tirzepatide: Comparing Residues Between Tirzepatide, GLP-1, and GIP
por: Wang, Lijing
Publicado: (2022)

Regulation of GIP and GLP1 Receptor Cell Surface Expression by N-Glycosylation and Receptor Heteromerization
por: Whitaker, Gina M., et al.
Publicado: (2012)

The Antiresorptive Effect of GIP, But Not GLP‐2, Is Preserved in Patients With Hypoparathyroidism—A Randomized Crossover Study
por: Skov‐Jeppesen, Kirsa, et al.
Publicado: (2021)

GIP/MZT1 proteins orchestrate nuclear shaping
por: Batzenschlager, Morgane, et al.
Publicado: (2014)

GLP-1 and GIP receptor agonists in the treatment of Parkinson’s disease: Translational systematic review and meta-analysis protocol of clinical and preclinical studies
por: Vaccari, Carolina, et al.
Publicado: (2021)

Physiological roles of the GIP receptor in murine brown adipose tissue
por: Beaudry, Jacqueline L., et al.
Publicado: (2019)

Role of Endogenous GLP-1 and GIP in Beta Cell Compensatory Responses to Insulin Resistance and Cellular Stress
por: Vasu, Srividya, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_fg2gvrpqo89thqlo1387ub97n0